Biomarkers (Biomarkers)

Publisher: Informa Healthcare

Journal description

Biomarkers is an exciting new journal which brings together work on all aspects of the rapidly growing field of biomarker research, encompassing their various uses and applications in one essential source.

Current impact factor: 2.52

Impact Factor Rankings

2015 Impact Factor Available summer 2015
2013 / 2014 Impact Factor 2.522
2012 Impact Factor 1.879
2011 Impact Factor 2.215
2010 Impact Factor 2.09
2009 Impact Factor 1.608
2008 Impact Factor 1.728
2007 Impact Factor 1.978
2006 Impact Factor 2.203
2005 Impact Factor 1.662
2004 Impact Factor 2.384
2003 Impact Factor 1.605
2002 Impact Factor 0.929
2001 Impact Factor 1.118
2000 Impact Factor 0.987
1999 Impact Factor 1.427
1998 Impact Factor 1.554
1997 Impact Factor 1.303

Impact factor over time

Impact factor
Year

Additional details

5-year impact 2.23
Cited half-life 4.70
Immediacy index 0.40
Eigenfactor 0.00
Article influence 0.61
Website Biomarkers website
Other titles Biomarkers (Online)
ISSN 1366-5804
OCLC 38266024
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Informa Healthcare

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 12 months embargo
  • Conditions
    • On author's personal website or institution website
    • Publisher copyright and source must be acknowledged
    • On a non-profit server
    • Must link to publisher version
    • Publisher's version/PDF cannot be used
    • NIH funded authors may post articles to PubMed Central for release 12 months after publication
    • Wellcome Trust authors may deposit in Europe PMC after 6 months
  • Classification
    ​ yellow

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: Urinary biomarkers are promising as simple alternatives to cystoscopy for the diagnosis of de novo and recurrent bladder cancer. To identify a highly sensitive and specific biomarker candidate set with potential clinical utility in bladder cancer. Urinary biomarker concentrations were determined by ELISA. The performance of individual markers and marker combinations was assessed using ROC analysis. A five-biomarker panel (IL8, MMP9, VEGFA, PTGS2 and EN2) was defined from the candidate set. This panel showed a better overall performance than the best individual marker. Further validation studies are needed to evaluate its clinical utility in bladder cancer.
    Biomarkers 07/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Little is known about polymorphic distribution of pharmacogenes among ethnicities, including the Deng people. In this study, we recruited 100 unrelated, healthy Deng people and genotyped them with respect to 76 different single-nucleotide polymorphisms by the PharmGKB database. Our results first indicated that the polymorphic distribution of pharmacogenes of the Deng people is most similar to CHD, suggesting that Deng people have a closest genetic relationship with CHD. Our data will enrich the database of pharmacogenomics and provide a theoretical basis for safer drug administration and individualized treatment plans, promoting the development of personalized medicine.
    Biomarkers 07/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: To assess endothelial cell selective adhesion molecule (ESAM) as predictor of cardiovascular mortality in diabetic dialysis patients (DDPs). ESAM, clinical and laboratory parameters were assessed in 73 DDP. Cardiovascular mortality was recorded in a 2 years' prospective observational study. Baseline ESAM was 17.1 (10.05-24.8) ng/ml and was correlated to phosphate (r = -0.42, p = 0.008), parathormone (r = -0.36, p = 0.048), albumin (r = -0.24, p = 0.048). ESAM significantly predicted cardiovascular death in univariate [HR = 1.03, 95% CI (1.006-1.054), p = 0.01] and multivariate [HR = 1.034, 95% CI (1.003-1.066), p = 0.03] Cox analysis. Time to cardiovascular death was shorter for patients with ESAM >12.44 ng/ml, p = 0.0045. ESAM is an independent predictor of cardiovascular mortality in DDP.
    Biomarkers 07/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: ADAM10 is a potential biomarker for Alzheimer's disease (AD). ADAM10 protein levels are reduced in platelets of AD patients. The aim was to verify the total blood and platelet ADAM10 gene expression in AD patients and to compare with mild cognitive impairment (MCI) and healthy subjects. No significant differences in ADAM10 gene expression were observed. Therefore, the decrease of ADAM10 protein in platelets of AD patients is not caused by a reduction in ADAM10 mRNA. Further studies must be performed to investigate other pathways in the down regulation of ADAM10 protein.
    Biomarkers 07/2015; DOI:10.3109/1354750X.2015.1062554
  • [Show abstract] [Hide abstract]
    ABSTRACT: To analyze the Ubiquitin-like with PHD and ring finger domains (UHRF) 1 expression in gastric cancer (GC). The concentrations of UHRF1 DNA in serum were compared between 187 GC patients and 56 healthy controls using real-time PCR. Immunohistochemical analysis using tissue microarrays was performed. UHRF1 DNA levels were significantly higher in GC patients compared to healthy controls (p < 0.001) and have associations with age and lymph node metastasis (LNM). The UHRF1 expression was significantly higher in tumor tissue than matched normal tissues (p < 0.001). The UHRF1 expression in serum and tissue may represent a novel biomarker for GC diagnosis and prognosis.
    Biomarkers 07/2015; DOI:10.3109/1354750X.2015.1061599
  • [Show abstract] [Hide abstract]
    ABSTRACT: Interleukin-27 is a new member of the IL-12 family which plays an important role in human carcinogenesis. To investigate whether polymorphisms in IL27 contribute to renal cell carcinoma (RCC) risk. These two polymorphisms were genotyped in 329 RCC patients and 386 healthy controls by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Significantly increased RCC risk was associated the G allele of both rs153109 and rs17855750 (rs153109: p = 0.006, OR = 1.364, 95%CI = 1.095-1.700; rs17855750: p = 0.001, OR = 1.768, 95%CI = 1.245-2.511). The present study provided evidence that rs153109 and rs17855750 were associated with increased risk for RCC, suggesting an important role IL-27 may play in nephrocarcinogenesis.
    Biomarkers 07/2015; DOI:10.3109/1354750X.2015.1062555
  • [Show abstract] [Hide abstract]
    ABSTRACT: Acute phase proteins (APPs) are proposed as potential markers of the health status in pigs. Circulating APPs in pigs co-infected with swine influenza virus and Pasteurella multocida. Serum APPs were measured in co-infected and control pigs with the use of commercial ELISA tests. All investigated APPs revealed significant changes in co-infected pigs during the study period. The concentration of C-reactive protein, haptoglobin and serum amyloid A (SAA) increased significantly at 2 dpi, before respiratory signs and fever were observed. Concentration of Pig-MAP increased significantly at 3 dpi. C-reactive protein and SAA reaction were rapid but short-lived. The concentration of Hp and Pig-MAP in serum also increased at very early stage of co-infection but remained elevated for a longer period of time. Maximal concentration of serum amyloid A correlated with the disease severity in pigs.
    Biomarkers 07/2015; DOI:10.3109/1354750X.2015.1061600
  • [Show abstract] [Hide abstract]
    ABSTRACT: We developed a specific hybridization assay for direct detection of long non-coding RNA urothelial carcinoma associated-1 (lncRNA-UCA1). Total RNA was extracted from urine pellet samples (bladder carcinoma patients and controls). Then, we compared the developed nanoassay with quantitative real time polymerase chain reaction (qRT-PCR) results in detection of urine UCA1 in bladder cancer and control samples. The sensitivity and the specificity of UCA1 nanoassay were 92.1% and 93.3%, respectively. The concordance of the two methods was 98%. Interestingly, all bilharzial benign cases showed negative lncRNA-UCA1 using both methods. UCA1-nanoassay is a valid test for direct detection of urine UCA1 for bladder cancer detection.
    Biomarkers 07/2015; DOI:10.3109/1354750X.2015.1062918
  • [Show abstract] [Hide abstract]
    ABSTRACT: To test the hypothesis whether serum advanced oxidation protein products (AOPP) are associated with increased acute kidney injury (AKI) after cardiopulmonary bypass (CPB) and could serve as a biomarker in this aspect, we performed a prospective cohort study. Thirty-five (22.3%) patients developed AKI, and 32 age- and gender-matched patients without AKI were selected as control. Serum AOPP 1 h after CPB were significantly higher among AKI patients compared with non-AKI patients (81.8 ± 18.6 versus 67.4 ± 12.5 μmol/L, p < 0.001), with an area under the receiver-operating characteristic (ROC) curve of 0.714. An optimal serum AOPP 1 h after CPB cutoff of 69.9 μmol/L had a sensitivity of 74%, specificity of 63% and a positive predictive value of 68% for predicting AKI. These results demonstrated that serum AOPP might be an early biomarker for AKI after CPB.
    Biomarkers 07/2015; DOI:10.3109/1354750X.2015.1062917
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to explore the clinical role of serum interleukin-17 in patients with non-small-cell lung cancer (NSCLC). IL-17 expression and microvessel density (MVD) were measured via immunohistochemistry in 58 NSCLC tissues. Serum IL-17 and VEGF levels in NSCLC patients (n = 43) and healthy controls (n = 37) were analyzed via enzyme-linked immunosorbent assay. Serum IL-17 was elevated and the levels positively correlated with VEGF concentration in NSCLC patients. Multivariate analyses revealed that serum IL-17 levels were an independent prognostic factor in NSCLC. IL-17 may play a role in NSCLC progression by promoting angiogenesis.
    Biomarkers 06/2015; 20(4):232-239. DOI:10.3109/1354750X.2015.1068853
  • [Show abstract] [Hide abstract]
    ABSTRACT: This review considers adipokines as predictive biomarkers for early onset post-traumatic knee osteoarthritis (KOA). Serum concentrations of leptin and resistin can predict radiographic changes and are elevated in early KOA, with higher leptin concentrations independently associated with more severe knee changes. Plasma concentrations of resistin are chronically elevated after injury. Leptin, resistin, chemerin and vistfatin induce catabolic enzymes associated with cartilage degeneration. Available literature on adipokines in post-traumatic KOA pathogenesis suggests that they could contribute to risk prediction of early onset post-traumatic KOA. Further research is needed to further understand the association between adipokines, synovitis and long-term outcomes in this population.
    Biomarkers 05/2015; DOI:10.3109/1354750X.2014.948914
  • [Show abstract] [Hide abstract]
    ABSTRACT: Assessing a diverse biomarker panel (NT-proBNP, TNF-α, galectin-3, IL-6, Troponin I, ST2 and sFlt-1) to detect subclinical cardiotoxicity after treatment with anthracyclines. Of 55 breast cancer patients biomarkers were assessed and echocardiography was performed one year after treatment with anthracyclines. 29.1% of patients showed abnormal biomarker levels: NT-proBNP in 18.2%, TNF-α and Galectin-3 in 7.3%. IL-6, troponin I, ST2 and sFlt-1 were normal in all patients. A correlation between left ventricular ejection fraction (LVEF) and NT-proBNP was observed (r = -0.564, p ≤ 0.01). The evaluated biomarkers do not contribute to early detection. Future research should focus on NT-proBNP.
    Biomarkers 05/2015; 20(2):1-6. DOI:10.3109/1354750X.2015.1040839
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aims: We examined the prognostic performance of measurements of cTnT concentrations at admission compared to discharge, in predicting major cardiovascular events during hospital admission and at six months follow-up. Methods and Results: The study population comprised 1351 patients with AMI and a mean age of 57.5 ± 11.4 years, of whom 66% were males. Cardiac TnT was measured on admission, 24 hours, and at discharge using the Elecsys 2010 [Roche Diagnostics]. No significant difference was found in patients who were cTnT negative on admission [n=345 (26%)] compared to the cTnT positive group [n=1006 (74%)], with respect to baseline characteristics, infarct pattern, biochemical data, and major cardiac events. In 475 patients [35%], serum cTnT levels were found to be higher on discharge from the CCU compared to admission/24 hour levels. A significantly greater proportion of patients had hypertension [63% vs. 50%, p< 0.001], higher systolic blood pressures [133, IQR 115 -154 vs. 127, IQR 111 -147, p< 0.001], history of previous AMI [17% vs. 9%, p< 0.001], and previous angina [17% vs. 9%, p= 0.001] if the discharge cTnT levels exceeded the admission/24 hour levels. A total of 120 deaths occurred during the study period with a significantly greater number of deaths recorded in patients whose discharge cTnT levels were higher than the admission/24 hour values [54(11%) vs. 66 (8%); p= 0.02, respectively]. Multivariable analysis using logistic regression showed that cardiogenic shock [ OR 5.92 {95% CI 2.86 - 12.28}; p< 0.001], cardiac failure [ OR 4.80 {95% CI 2.61 – 8.82}; p< 0.001], cerebrovascular accident [ OR 3.95 {95% CI 1.48 – 10.58}; p= 0.01], complete heart block [ OR 3.50 { 95% CI 1.22 – 10.09}; p= 0.02], increasing age [ OR 1.04 {95% CI 1.02 – 1.01}; p< 0.001], and a greater discharge cTnT value [ OR 1.61 (95%CI 1.01 - 2.56); p=0.04] conferred a significantly higher odds of mortality. Conclusions: This study shows that, in addition to cardiogenic shock, cardiac failure, cerebrovascular accident, complete heart block, and increasing age, higher cTnT level at discharge is an important independent predictor of mortality in patients with AMI, and could further improve the prognostic accuracy of admission values of cTnT, based on relevant patents.
    Biomarkers 04/2015;